They are introducing them early in their protocols
Loyo P, Bohra C, Bhatia K, Baruch L, Eng C, Peters JJ
In the phase III clinical developmental programs of the DPP-4 inhibitors, non-inferiority was demonstrated after 1 and 2 years for these substances compared to sulfonylureas with respect to the glycaemic parameters HbA1c as well as fasting- and post-prandial plasma glucose concentrations
Seeing the effects of GLP-1 medications through medical imaging requires attentiveness rather than alarm
However, when compared to SGLT2 inhibitors, GLP-1 receptor agonists are less effective for kidney outcomes, including albuminuria and eGFR decline, but remain superior to DPP-4 inhibitors, sulfonylureas, and basal insulin [143,144]